Remove Clinical Development Remove Clinical Research Remove Pharmaceuticals
article thumbnail

Harnessing AI and Real-World Data: The Future of Clinical Development

PPD

The pharmaceutical industry is currently experiencing a significant transformation. The convergence of real-world data (RWD), technology and artificial intelligence (AI) is playing a vital role in accelerating drug development. Ready to learn more about convergence of real-world data and technology for clinical trials?

article thumbnail

The AI model that is changing clinical trial design

Drug Target Review

Chief Executive Officer Steve Herne has spent more than 25 years in clinical research, with senior roles at WCG, Bioclinica and Covance. Unlearn’s digital twins are now in use in both early and late-stage clinical trials, with adoption continuing to grow. Unlearn is one of the few companies applying this approach at scale.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Redefining Acceleration of the Drug Development Journey

PPD

According to Citeline’s Pharmaprojects tracking, some 21,000 molecules are in the drug development pipeline right now – and they are all being developed because they have the potential to change and save lives. Accelerate your drug development and clinical trial goals and benefit from our 360° CDMO and CRO solutions and expertise.

article thumbnail

Looking for Opportunities to Accelerate Clinical Research in Rare Diseases

LifeSciVC

It’s important to recognize that for many large pharmaceutical and biotechnology companies, compounds that have the potential to treat a rare disease of significant unmet need might become lower strategic priority than those that have mass market potential.

article thumbnail

Navigating Varying Regulatory Feedback in Clinical Oncology Trials: A Guide for Clinical Research Professionals

Conversations in Drug Development Trends

For clinical research professionals, this journey often involves reconciling differing feedback from regulatory agencies, each with unique standards, priorities, and expectations. As we look towards future developments in oncology and beyond, the importance of strategic regulatory planning and execution cannot be overstated.

article thumbnail

The Power of Personalization Amid the Changing CRO Landscape

Conversations in Drug Development Trends

These survey results also highlight the importance of evaluating a variety of potential CRO partners of different sizes to choose the best match for your clinical development goals and corporate culture.

article thumbnail

FSP Engagements Continue to Gain Popularity, Drive Success

PPD

The PPD clinical research business of Thermo Fisher Scientific conducts an annual survey of more than 150 leaders at pharmaceutical companies around the globe to assess trends in drug discovery and development, including preferences around outsourcing and functional service provider (FSP) utilization.